Imaging governance, built for multicentre clinical trials.
WIDEN centralises imaging transfer, quality control, review workflows and regulatory archiving within one controlled environment — engineered to improve consistency, traceability and endpoint reliability across every participating site.
Imaging data need governance, not simple storage.
In complex clinical trials, imaging is generated across multiple sites, scanners and operating environments. Without structured governance, variability compounds, workflows fragment, and the reliability of imaging endpoints is put at risk.
An imaging core lab should never function as a passive repository. It should operate as a controlled infrastructure that safeguards quality, consistency and regulatory readiness across the entire study lifecycle.
A platform-driven model for imaging governance.
Dixit operates as an imaging CRO powered by WIDEN, a proprietary core lab platform built specifically for multicentre clinical trials. We centralise imaging operations through structured workflows that keep every dataset controlled from acquisition to archive.
By uniting operational control and scientific oversight in one environment, WIDEN turns fragmented imaging workflows into scalable, regulatory-ready clinical infrastructure.
- Secure imaging transfer. Centralised, protected DICOM upload and exchange across global clinical sites.
- Protocol compliance verification. Acquisition checked against imaging charter criteria before data reaches analysis.
- Quality control oversight. Proactive identification of technical deviations across every participating site.
- Review management. Structured, blinded reviewer workflows designed for consistency and endpoint reliability.
- Audit-ready traceability. Complete chain of custody across acquisition, review and workflow progression.
- Regulatory archiving. Long-term, inspection-ready imaging archives aligned with regulatory expectations.
Illustrative interface — sample data, not client results.
What the imaging core lab delivers.
Every layer of imaging operations, configured to your protocol and held to the same controlled standard across all participating sites.
Centralised imaging governance
A unified operational environment for imaging transfer, review, quality control and workflow monitoring.
Quality-controlled workflows
Structured processes designed to identify technical deviations before they can affect endpoint evaluation.
End-to-end traceability
A complete audit trail spanning acquisition, review activities and workflow progression.
Regulatory-ready infrastructure
Inspection-ready imaging governance aligned with regulatory expectations and multicentre study requirements.
Multicentre operational oversight
Centralised visibility across global imaging activities, participating sites and workflows.
Operational control improves endpoint reliability.
Imaging variability can weaken statistical robustness, delay submissions and increase operational risk. A governed core lab model gives sponsors that control back.
- Reduce workflow fragmentation across sites, vendors and imaging modalities.
- Improve imaging consistency through standardised acquisition and review.
- Strengthen endpoint reproducibility with controlled, blinded reads.
- Increase operational visibility across global imaging activities in real time.
- Support inspection readiness with audit-ready records at every stage.
The result is imaging infrastructure that is more controlled, more scalable and regulatory-ready by design.
The core lab platform, peer-reviewed.
WIDEN and the methods behind it are described in the peer-reviewed literature, not only in our own materials. See all publications.
- 177Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial (opens in a new tab)
- Sequential 177Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study (opens in a new tab)
- 177Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial (opens in a new tab)
- ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901) (opens in a new tab)
- UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naïve prostate cancer (clinical trial protocol) (opens in a new tab)
- TheraP: a randomized phase 2 trial of 177Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603) (opens in a new tab)
- Automatic liver detection and standardised uptake value evaluation in whole-body Positron Emission Tomography/Computed Tomography scans (opens in a new tab)
- The Strategies to Homogenize PET/CT Metrics: The Case of Onco-Haematological Clinical Trials (opens in a new tab)
- WIDEN: A tool for medical image management in multicenter clinical trials (opens in a new tab)
Let’s strengthen your imaging governance strategy.
Discover how WIDEN helps sponsors centralise imaging operations and improve endpoint reliability across multicentre studies.